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Abstract
Whilst many chronic graft versus host disease (cGVHD) biomarkers have been previously reported, few have
been verified in an independent cGVHD cohort. We aimed to verify the diagnostic accuracy of previously
reported markers of cGVHD in a multi-centre Chronic GVHD Consortium. A total of 42 RNA and 18 protein
candidate biomarkers were assessed amongst 59 cGVHD cases and 33 matched non-GVHD controls. Total RNA
was isolated from PBMC, and RNA markers were quantified using PCR. Serum protein markers were quantified
using ELISA. A combined 3 RNA biomarker (IRS2, PLEKHF1 and IL1R2) and 2 clinical variables (recipient CMV
serostatus and conditioning regimen intensity) panel accurately (AUC 0.81) segregated cGVHD cases from
controls. Other studied RNA and protein markers were not confirmed as accurate cGVHD diagnostic bio-
markers. The studied markers failed to segregate higher risk cGVHD (per overall NIH 0-3 score, and overlap
versus classic cGVHD status). These data support the need for multiple independent verification studies for
the ultimate clinical application of cGVHD diagnostic biomarkers.
Keywords: chronic graft versus host disease; diagnostic biomarkers
Received 23 July 2016; Accepted 18 September 2016
Conflict of interest
The authors report no relevant conflicts of interest.
Introduction
Chronic graft versus host disease (cGVHD) is an
important cause of late morbidity, mortality, impaired
quality of life and prolonged immune suppressive
treatment after allogeneic haematopoietic cell trans-
plantation (HCT) [1–3]. This heterogeneous disease
has protean manifestations, and non-invasive blood
biomarkers may provide valuable information regard-
ing cGVHD diagnosis and activity. Beyond diagnos-
tic markers, multiple other promising applications
have been recently reviewed [4,5].
Multiple candidate cGVHD diagnostic biomarkers
have been previously reported [4] however progress
has been limited by lack of verification by other
investigators using independent patient cohorts. Inde-
pendent verification of candidate biomarkers repre-
sents an integral component of the path towards
ultimate clinical application [5]. Additionally, current
understanding of variation in candidate markers
according to cGVHD subtypes, organ involvement
and severity is limited.
The primary objective of this analysis was to ver-
ify the diagnostic accuracy of previously reported
cGVHD biomarkers in an independent cohort. Sec-
ondary objectives were to examine variation in stud-
ied markers according to cGVHD sub-type, organ
involvement and severity.
Material and methods
Parent cohort study
A national cohort of cGVHD subjects has been
assembled through a multicentre effort of the Chronic
GVHD Consortium. The observational protocol has
been approved by the respective Institutional Review
Boards at participating centres, and all subjects
Original Article
VC 2016 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res January 2017; 3: 3–16
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are
made.
The Journal of Pathology: Clinical Research
J Path: Clin Res January 2017; 3: 3–16
Published online 27 September 2016 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/cjp2.58
provided informed consent. Patients enrolled in the
cohort were allogeneic HCT recipients 2 years of age
or older with cGVHD requiring systemic immuno-
suppressive therapy, including both those with classic
cGVHD and those with overlap subtype of cGVHD
[6]. Cases were classified as incident (enrollment less
than 3 months after chronic GVHD diagnosis) or
prevalent (enrollment three or more months but less
than 3 years after cGVHD diagnosis). Primary malig-
nancy relapse, and inability to comply with study
procedures were exclusion criteria. At enrollment and
every 6 months thereafter, physicians and patients
report standardised information on cGVHD organ
involvement and symptoms. Incident cases had an
extra assessment time point 3 months after enroll-
ment. Chronic GVHD severity was calculated from
individual organ scoring provided by clinicians using
the NIH consensus scoring (mild, moderate, severe)
[6]. Standardised chart review following each visit
abstracted objective medical data (including ancillary
testing and laboratory results), medical complications
and medication profiles. Control subjects met similar
eligibility criteria (2 years of age or older, prior allo-
geneic HCT, no evidence of malignancy relapse and
provision of informed consent), and had no evidence
of cGVHD. All cGVHD and control subject samples
used in this study were obtained at Fred Hutchinson
Cancer Research Center.
Selection of chronic GVHD cases and controls
Chronic GVHD and control cases were matched
based on time from transplant to sample draw (62
months), conditioning regimen intensity, donor type
and prior classic acute GVHD. Information about
donor chimerism at time of sample collection was
not available. Malignancy relapse was present prior
to sample collection in one subject only. A total of 8
subjects had active infectious complications noted at
time of sample collection: viral upper respiratory
infection (n5 2), sinusitis (n5 2), fungal oesophagi-
tis (n5 1), bacterial conjunctivitis (n5 1), candida
vaginitis (n5 1), cytomegalovirus (CMV) retinitis
(n5 1). The majority of infections (n5 7) were
amongst chronic GVHD cases (versus controls n5 1).
Amongst the selected cGVHD cases and controls
for this study, a total of 31 individual subjects
(cGVHD cases n5 13, controls n5 18) had samples
previously utilised for B cell receptor signalling and
B cell subset analyses only (did not examine the cur-
rently studied chronic GVHD diagnostic RNA or pro-
tein markers) [7]. As well, 67 individual subjects
(cGVHD cases n5 45, controls n5 22) had samples
previously utilised in a validation set of FHCRC
patients for testing CXCL9 only (supplementary
material, Table S5) [8].
Clinical variables
Comprehensive clinical data collected included the
following: Date of sample collection from both time
of HCT and separately time from cGVHD initial
onset; age of the patient; donor/recipient gender
matching (female/male versus others); disease diag-
nosis/HCT indication (acute myelogenous leukemia,
acute lymphoblastic leukemia, multiple myeloma,
non-Hodgkin lymphoma, myelodysplastic syndrome,
chronic myeloid leukemia, chronic lymphocytic leu-
kemia, Hodgkin lymphoma, aplastic anemia, others);
race and Hispanic ethnicity status; donor age; donor/
recipient CMV serostatus; graft source (peripheral
blood mobilised, bone marrow, umbilical cord
blood); donor type (HLA-identical sibling, HLA-
mismatched relative, matched unrelated or mis-
matched unrelated donor); transplant conditioning
(myeloablative, reduced-intensity/non-myeloablative);
immune suppression used as initial GVHD prophy-
laxis; use of in vivo or ex vivo T cell depletion; ante-
cedent occurrence of acute GVHD; current immune
suppression at time of sample collection (including
individual systemic agents, dose in mg/kg/day of
prednisone, and topical agents); cGVHD status (inci-
dent versus prevalent case); cGVHD sub-type (classic
versus overlap subtype); Overall NIH Global severity
score (none, mild, moderate, severe) and severity
scoring for individual affected organ sites (0-3 score
for each including skin, mouth, eye, GI, liver, joint/
fascia, genital and lung).
Candidate markers considered
A comprehensive literature search was conducted to
summarise previously reported RNA and protein
diagnostic markers of cGVHD. A total of 42 RNA
biomarkers and 18 protein biomarkers were respec-
tively examined by qPCR and ELISA. Candidates are
summarised in supplementary material, Table S1.
Endogenous controls (18S, GAPDH, ACTB) and
cell-lineage markers (CD14, CD3D, CD56, NGAL,
CD19, ITGAX, CD66b) were also examined using
qPCR.
Procedures
RNA extraction and quantification. Blood samples
were collected in heparin-coated tubes for peripheral
blood mononuclear cell (PBMC) isolation. Samples
were frozen in aliquots of 5 million cells. Total RNA
was extracted using Rneasy Mini Kit (Qiagen,
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Valencia, CA) following the manufacturer’s protocol.
Total-RNA concentration was measured using Nano-
DropVR ND-1000 (NanoDrop Technologies, Wilming-
ton, DE) and the integrity of total-RNA was assessed
using the RNA NanoChip with the Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA),
with an RIN >7 accepted as good quality RNA to be
used for this study. Total-RNA was stored in 280 8C
until further use for microarray or qPCR.
Quantitative real-time PCR (qPCR). Two hundred and
fifty nanograms of extracted total RNA was proc-
essed through steps of reverse transcription (RT,
cDNA synthesis, Superscript II, Invitrogen, Carlsbad,
CA), specific target amplification (STA) and sample
dilution using gene specific primers and Taqman
probes (subsequently annotated as TaqMan assays)
for 46 genes (Life Technologies, Foster City, CA)
(supplementary material, Table S1). A total of 1.56
ng of cDNA per sample in 1.25 lL generated using
SuperScript First-Strand Synthesis System for RT-
qPCR (Invitrogen Technologies Inc., Carlsbad, CA)
from 250 ng total RNA starting template along with
1.25 lL of the pooled TaqMan Gene Expression
Assays (46 genes, except 18S) and 2.5 lL TaqMan
PreAmp Master Mix (Life Technologies, Applied
Biosystems, Foster City, CA) to 5 lL final volume
was amplified in a specific target amplification
(STA) in the Eppendorf vapo.protectTM Mastercycler
(Eppendorf, Hauppauge, NY) for a total of 18 cycles
then diluted 1:5 with DNA Suspension Buffer
(10 mM Tris, pH 8.0, 0.1 mM EDTA) (TEKnova,
PN T0221). For subsequent microfluidic qPCR 2.25
lL of the preamplified cDNA was mixed with 2.25
lL TaqMan Universal PCR Master Mix (Applied
Biosystems) and 0.25 lL Sample Loading Reagent
(Fluidigm, San Francisco, CA) and pipetted into the
sample inlets of a Dynamic Array 96.96 chip (Fluid-
igm). TaqMan Gene Expression Assays (Applied
Biosystems) for the 45 genes plus 18S as endogenous
control gene were diluted with Assay Loading Rea-
gent (1:2) (Fluidigm) and 5 lL was pipetted into the
assay inlets of the same Dynamic Array 96.96 chip.
After distributing assays and samples into the reac-
tion wells of the chip in the IFC controller (Fluid-
igm), the qPCR reactions were performed in the
BioMark RT-qPCR system for a total of 40 cycles.
Data was analysed using the BioMark RT-qPCR
Analysis Software Version 2.0 and raw Ct values
were exported into Microsoft Excel (Microsoft Office
2007, Microsoft Inc., USA) for calculation of delta
Ct values using 18S as endogenous control gene.
ELISA assay. Haptoglobin ELISA was run using Hap-
toglobin Human ELISA Kit from Abcam
(Cambridge, MA), anti-dsDNA: anti-double stranded
DNA using Anti dsDNA IgG Assay from Genway
(San Diego, CA), and B cell activating factor
(tumour necrosis factor (ligand) superfamily, member
13b) (BAFF) from R&D Systems (Minneapolis, MN)
using manufacturer’s protocol. ELISA assays were
optimised for MSD. All other ELISA assays were
run using R&D System’s DuoSet
VR
ELISA Develop-
ment Systems (R&D Systems, Minneapolis, MN).
The ELISA kits are as follows: CC16: clara cell
secretory protein, IL-10: interleukin 10, IL-1Ra:
interleukin 1 receptor antagonist, IL-6: interleukin,
sCD13: soluble CD13 (aminopeptidase-N), sIL-2R:
soluble alpha chain of the IL-2 receptor, IL-8: inter-
leukin 8, TNFa: tumour necrosis factor alpha, IL-17:
interleukin 17, IL-15: interleukin 15, elafin, MIG:
chemokine (C-X-C motif) ligand 9, IL-1b: interleukin
1 beta, TGF-b1: transforming growth factor beta1.
ELISA using R&D System’s DuoSet
VR
ELISA Devel-
opment Systems were performed using chemiluminis-
cence detection method of Meso Scale Discovery
(MSD) (Rockville, MD). The assays were run follow-
ing the manufacturer’s protocol. Briefly, 1% Blocker
A was used to dilute samples. We used 20 ng to 500
ng capture antibody to coat the MULTI-ARRAY
VR
96-well Plate (MSD) (20 ng for elafin, 40 ng for
sCD13, 100 ng for CC16, IL-10, IL-6, sIL-2R, IL-15,
TGF-b1, 200 ng for IL-8, TNFa, IL-17, IL-1b, 300
ng MIG and 500 ng IL-1Ra) and incubated at 4 8C
for 24 h. After the coating step the coating antibody
was removed and 150 lL of Blocker A was added to
block by shaking at 450 rpm for 1 hr at 25 8C. The
plate was washed for 3 times with wash buffer (PBS
with 0.05% Tween-20). After the washing step the
standards and samples were added with appropriate
sample dilution (1:2 for IL-6, IL-15, TNFa, IL-17,
IL-1Ra; 1:5 for IL-10, TGF-b1, IL-1b, MIG; 1:10 for
sIL-2R; 1:20 for elafin; 1:25 for IL8; 1:50 for CC16
and 1:250 for sCD13). The plate was sealed and
incubated with shaking (450 rpm) at 25 8C for 2 h.
After the incubation with samples and standards the
plates were washed as before. After the washing step,
optimised amount of detection antibody was added to
the wells (1 ng for IL-8; 2.5 ng for IL-6; 5 ng for IL-
1Ra and sIL-2R; 7.5 ng for IL-17 and IL-10; 10 ng
for IL1b, MIG and elafin; 15 ng for TGF-b1; 20 ng
for sCD13; 25 ng for IL-15 and TNFa; and 100 ng
for CC16). The plate was sealed and incubated with
shaking (450 rpm) at 25 8C for 2 h. The plate was
washed as before. 50 ll SULFO-TAG Streptavidin
(1:1500) (MSD) was added and incubated on a
shaker at 450 rpm for 45 min in dark. Wash the plate
and read immediately using SECTOR S 600 instru-
ment (Meso Scale Discovery, Rockville, MD).
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Data analysis. Raw gene expression and protein data
preprocessing utilised imputation, quantile normalisa-
tion and log2 conversion. Missing data was imputed
with an average of 10 nearest neighbours. Clinical vari-
ables were standardised for regression analysis by
reducing them to a standard score, xi-u/sd, in which xi
denotes raw data, u as mean of xi vector, and sd as
standard deviation. All data analyses were performed
by using established libraries and in-house programmes
under R 3.2.1 (https://www.r-project.org/). Sample clus-
tering and heatmap visualisations were done using cor-
relation similarity metric and average linkage clustering
[9]. Between Group Analysis (BGA) was used to clas-
sify samples. The relative similarity of gene expression
and protein measurements in samples were set by
Correspondence Analysis (COA), and Principal compo-
nent analysis [10]. Two methods were used to select
biomarkers, differential analysis and LASSO [11,12].
Differential analysis was performed by using R limma
packages, with fitting linear model and empirical
Bayes, adjusted with BH, and derived p-value (p<
0.05) from moderated t-statistic [13]. LASSO was also
used as a penalised regression method for variable bio-
marker selection [14].Logistic regression was used to
estimate discriminant accuracy.
The repeated random sub-sampling method was
used for prediction and validation, in which samples
were randomly split into a training set (80%) and
validating set (20%), with iteration of 1000. The
training set was used to fit logistic models and the
validating set for predicting accuracy. ROC curve
was estimated from the discriminant accuracy. We
only considered partial Area Under Curve (AUC)
with ci.alpha5 0.9, bootstrap 100 times and high
sensitivity >90% unless specifically noted.
Selection of biomarkers adjusted to their associa-
tions to clinical variables were done by canonical cor-
responding analysis (CCA) and canonical correlation
(CC) were used to adjust the biomarkers to clinical
variables, and estimated correlation correlations
between two data matrices, the biomarker matrix and
clinical matrix. Association between biomarkers and
clinical variables were estimated by multivariate multi-
ple regression in standard linear model function and
the significant test (p-values; significant levels <0.05)
were calculated by multivariate analysis of variance.
Results
Patient characteristics
Chronic GVHD case and control patient characteristics
are summarised in Table 1. There were no significant
differences between groups for age, time from HCT to
sample collection, major patient, disease and trans-
plantation variables, history of prior acute GVHD, or
prior use of T cell depletion. In contrast, initial
GVHD prophylaxis utilised and prednisone dose at
time of sample collection differed.
Diagnostic accuracy of studied biomarker
candidates
A total of 92 biologic samples (59 cGVHD and 33
controls) were used to examine the performance of
previously published cGVHD diagnostic biomarkers
for discrimination between cGVHD and controls in
this independent sample set. Levels of the tested 42
RNA and 18 protein biomarkers (supplementary
material, Table S1) were first compared across
cGVHD (inclusive of incident and prevalent) versus
control groups. Clinical variables (methods, supple-
mentary material, Table S2) were collected for each
subject.
Classification profile of all biomarker candidates
To evaluate the overall performance of existing bio-
markers for discriminating cGVHD and controls, we
performed unbiased clustering of all samples by cor-
relation similarity with all biomarkers (Figure 1A
and B). We next classified these samples by Between
Group Analysis (BGA), a method with much higher
sensitivity than clustering (Figure 1C and D). This
indicated that the assembled panel of 42 RNAs and
18 protein biomarkers did not perform well in an
unbiased analysis to distinguish cGVHD cases from
controls, with considerable overlap and gene and pro-
tein measures across different samples.
Selection of significant biomarkers by supervised
analysis to distinguish cGVHD
We next selected significant biomarkers by supervised
differential analyses. Only one protein (anti-dsDNA)
and 7 RNA candidates (IL1R2, IRS2, CD66b, PDGF,
VSIG4, AREG, PLEKHF1) were significantly (p<
0.05) different in expression between cGVHD cases
and controls whereas high levels of variances across the
other markers resulted in a lack of overall significance
for the remaining candidate markers (supplementary
materials, Table S3 and S4). Given these results, we
focused our subsequent analyses only on the 7 RNA
markers as a potential biomarker assay (Figure 2A) as
a single significant protein is unlikely to be sufficient
to accurately discriminate cGVHD cases versus con-
trols. We next employed logistic regression to estimate
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the discriminant accuracy by the 7 RNA biomarkers.
We used partial Area Under Curve (AUC, with >90%
sensitivity AUC) in a receiver operating characteristic
(ROC) to represent the discriminant accuracy of this
panel. As shown in Figure 2B, the partial AUC for
these 7 RNA biomarkers was low, at 52% for cGVHD
diagnosis. LASSO was also used to enhance the selec-
tion of informative biomarkers. A total of 8 biomarkers
Table 1. Summary of chronic GVHD and control subject clinical characteristics
Cases* (n5 59) Controls (n5 33) p-value
Patient age at study entry, median (range) 51 (19-72) 54 (24-75) 0.33
Donor age at transplant, median (range) 44 (17-71) 42 (19-61) 0.80
Months from HCT to sample, median (range) 12 (4-34) 12 (5-33) 0.60
Prednisone dose at sample, median (range) 0.12 (0.0-0.99) 0 (0.0-0.41) <0.0001
Race, % 0.15
White 88 97
Other 12 3
Hispanic, % 0.56
No 97 94
Yes 3 6
Disease diagnosis, % 0.96
ALL 14 15
AML 41 39
MDS 17 12
HL/NHL 15 15
Other 14 18
Patient CMV serostatus at HCT, % 0.40
Negative 42 52
Positive 58 48
Donor CMV serostatus at HCT, % 0.52
Negative 64 58
Positive 36 42
Donor/patient gender, % 0.53
Other 73 79
F/M 27 21
Donor type, % 0.91
Matched related 51 52
Matched unrelated 34 30
Mismatched 15 18
Stem cell source, % 0.10
PBSC 86 70
Bone marrow 10 27
Cord blood 3 3
Conditioning, % 0.91
Myeloablative 68 67
Non-myeloablative 32 33
GvHD prophylaxis 0.0003
CNI1MTX6 other 58 36
CNI6 other 42 39
Other 0 24
Prior/current T-cell depletion, % 0.83
No 86 85
Yes 14 15
Prior acute GVHD 0.40
No 17 24
Yes 83 76
*cGVHD cases (inclusive of both incident and prevalent cGVHD cases) are reported together here for comparison against non-GVHD control subjects. Incident
and prevalent cGVHD cases did not significantly differ from each other for these studied variables (table), except for the following: donor CMV positivity (inci-
dent 23% versus prevalent 50%, p5 0.03); donor type (incident: 35% matched related, 55% unrelated, 10% mismatched; prevalent 68% matched related, 11%
unrelated, 21% mismatch, p5 0.002); median time from HCT to sample collection (incident 12 months, range 4-19 months versus prevalent 13 months, range
11-34 months, p5 0.001).
*HCT – allogeneic haematopoietic cell transplantation; prednisone dose – presented in mg per kg recipient body weight per day (mg/kg/day); ALL – acute lym-
phoblastic leukemia, AML – acute myelogenous leukemia, MDS – myelodysplastic syndrome, HL – Hodgkin’s lymphoma, NHL – non-Hodgkin’s lymphoma; CMV –
cytomegalovirus; F – female, M – male; PBSC – peripheral blood mobilised stem cells; CNI – calcineurin inhibitor, MTX – methotrexate; GVHD – graft versus
host disease.
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(ARRB1, BCAT1, CD56, CD66b, GAPDH, IL1R2,
IRS2, VSIG4) were selected, but their discriminant
performance was similar to that of our earlier
approach (Figure 2C), confirming that there is sig-
nificant heterogeneity between cases in controls that
may be specific to each sample set previously
analysed.
Discriminant performance of biomarkers adjusted
by clinical variables
As adjustment of the selection of biomarkers based
on their associations with clinical variables could
potentially improve their discriminant performance,
we refined the selected biomarker panel by the
Figure 1. Overall performance of protein and RNA biomarkers in discriminating samples of chronic GVHD and control. Both of cluster-
ing and BGA (Between Group Analysis) were employed to classify the control and GVHD, including prevalent and incident. (A and B)
heatmap based on protein biomarkers and RNA biomarkers respectively. (C and D) classification by BGA using proteins and RNA bio-
markers respectively.
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measured clinical variables. We performed canonic
corresponding analysis (CCA) and canonic correla-
tion (CC) to adjust the selected 7 biomarkers to clini-
cal variables. Both CCA and CC consistently
revealed three biomarkers (IRS2, PLEKHF1 and
IL1R2) as the best biomarkers for cGVHD, (Figure
3A). These three biomarkers could separate prevalent
cGVHD samples from controls (Figure 3B) and
improved the partial AUC to 54% (Figure 3C) from
52% (Figure 2B).
Figure 2. Samples classified by selected RNA biomarker. Samples were classified by RNA biomarker selected by differential
analysis and LASSO respectively. (A) classification by 7 biomarkers selected by differential analysis (p< 0.05) by using
BGA. This 7 biomarkers are listed in the insert table. (B) ROC curve derived from the 7 differential biomarkers. (C) ROC
curve derived from biomarkers selected by LASSO. Insert shows the LASSO regression function and genes selected by
LASSO.
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Combining RNA biomarkers with clinical variables
can improve the discrimination of cGVHD
We further examined the discriminant performance
of combining these adjusted biomarkers with clinical
variables. We first selected clinical variables that
contribute significantly to the biomarker expression.
We performed multivariate multiple regression to
estimate the association between clinical variables
and 7 selected RNA biomarkers and 3 adjusted
biomarkers (IRS2, PLEKHF1 and IL1R2) respectively
(Figure 4, left and middle panel). The association of
these clinical variables to GVHD phenotype was also
examined as a control (Figure 4, right panel). These
association analyses consistently revealed recipient
CMV status as the most significant variable (p< 8E-
06) contributing to RNA biomarkers, followed by the
dose of prednisone at the time of sample collection
and the time from cGVHD onset to sample collection
(Figure 4 right panel); in fact steroid dose and the
Figure 3. Performance of adjusted biomarkers. (A) The plot of canonical correspondence analysis (CCA) showed the variance contribu-
tion of each RNA biomarker to clinical variables. The length and direction of each arrow denote its importance of variance contribu-
tion (longer arrow5 larger contribution here at given direction). The insert shows the biomarkers ranked by CC coefficient score and
three top biomarkers, IRS2, PLEKHF1 and IL1R2. (B) Samples classified by the three top adjusted biomarkers. (C) ROC curve derived
from the three top adjusted biomarkers.
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length of time of sampling after cGVHD onset had an
80% partial AUC and were highly correlated with the
diagnosis of cGVHD, as expected. Thus these two
variables, which are inherent to the disease process,
were not considered for subsequent biomarker model-
ling. When only recipient CMV status was used in
combination with the 3 adjusted RNAs (Figure 5A,
supplementary material, Figure S1), the partial AUC
reached 66% (Figure 5B). One sub-type of cGVHD
and one subtype of control, cGVHD with CMV nega-
tive and control with CMV positive, were mostly sep-
arated. The inclusion of a second clinical variable,
transplant conditioning intensity (p< 0.0184, Figure 4
middle panel), improved discrimination of cGVHD
(Figure 5C), as two subtypes, CMV_negative_myeloa-
blative_cGVHD and CMV_positive_non-myeloablative_
control, were clearly separated. The partial AUC was
81.1% for a sensitivity of 60%, or a partial AUC of
73% with a sensitivity of >90% (Figure 5D). This
indicated that the combination of two clinical varia-
bles and 3 RNA biomarkers could now discriminate
cGVHD cases from controls.
Discrimination of prevalent versus incident
chronic GVHD
Employing a similar strategy to that mentioned above
for discriminating cGVHD versus controls, we used
Figure 4. Association of clinical variables with the selected biomarkers and phenotypes. Left and middle panel showed all clinical var-
iables association with 7 selected biomarkers and 3 adjusted biomarkers (IRS2, PLEKHF1 and IL1R2) respectively, whilst the right
panel presents clinical variables association with chronic GVHD and control phenotypes.
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Figure 5. Discrimination of GVHD against control by three RNA biomarkers combined with clinical variables. (A and B) classification of
GVHD versus control by three adjusted biomarkers (IRS2, PLEKHF1 and IL1R2) combined with one clinical variable, patient CMV status.
(A) classification of GVHD versus control by using BGA. The suffix number in the phenotype label denotes the CMV status, with 1 and 2
respectively representing CMV negative and positive, so GVHD.1 represents GVHD with negative CMV, and control.2 as CMV positive con-
trol. (B) ROC curve derived from three adjusted biomarkers combined with patient CMV status. (C and D) discrimination of GVHD versus
control by three adjusted biomarkers combined with two clinical variables, patient CMV and conditioning regimen intensity. (C) discrimina-
tion of GVHD versus control by BGA. The second suffix number denotes the type of conditioning regimen intensity, 1-myeloablative and
2-non-myeloablative, GVHD.1.1 as GVHD with CMV negative and myeloablative therapy and control.2.2 as CMV positive control and non-
myeloablative therapy. (D) ROC curve derived from three adjusted biomarkers combined with two clinical variables.
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differential analysis (p< 0.05) to select a subset of 5
biomarkers (CD56, FoxP3, IRS2, CXCR6, CD19)
that could separate the incident and prevalent
cGVHD groups (Figure 6A). A subset of 3 bio-
markers (CD56, IRS2 and CD19) were selected by
adjusting by total clinical variables through CCA and
CD, and then multivariate multiple regression was
run to find variables that significantly contributed to
these three adjusted 3 RNAs (Figure 6B). After com-
bining biomarkers with the most significant clinical
variable, NIH 0-3 score for GI involvement
(p< 0.00622, Figure 6B), we could now discriminate
the subtypes of prevalent and incident cGVHD (Fig-
ure 6C, supplementary material, Figure S2), with an
AUC of 62% (Figure 6D). Combining this data with
a second clinical variable, NIH 0-3 score for mouth
involvement (p< 0.02815, Figure 6B), the biomarker
and 2 variable clinical panel could easily and com-
pletely discriminate the prevalent and incident
GVHD subtypes with an AUC of 100% (Figure 6E).
Analysis according to chronic GVHD
characteristics
In a separate analyses, we examined the association
of the most significant biomarkers with cGVHD
characteristics including overall NIH 0-3 score and
cGVHD sub-types (overlap versus classic cGVHD).
Correlation coefficient, linear models and CCA were
employed to analyse these associations. No signifi-
cant associations were identified between the studied
biomarkers and overall NIH 0-3 severity, or chronic
GVHD sub-type (overlap versus classic).
Discussion
Numerous prior studies have reported associations
between molecular and cellular biologic markers and
cGVHD diagnosis [4]. However, independent verifi-
cation of these findings is largely absent, and this
represents a major challenge to advancement of the
field and potential clinical application of these find-
ings [5]. To address this need, we conducted an inde-
pendent verification study of previously published
RNA and protein cGVHD diagnostic markers. Our
results support that a 3 RNA marker panel (IRS2,
PLEKHF1 and IL1R2) together with two routinely
collected clinical variables (recipient CMV serostatus
and conditioning regimen intensity) can distinguish
cGVHD cases from non-GVHD controls with a high
degree of accuracy.
These positive findings support previous published
evidence: The 3 key RNA markers have been previ-
ously shown to discriminate cGVHD from non-
GVHD controls in prior discovery studies [15,16] As
well, these identified markers may provide insights
into the pathogenesis of the syndrome: IRS2 is an
important component of IL-4 receptor signalling;
downstream signalling events following IRS phos-
phorylation, including PI3 kinase, are required for
IL-4-induced proliferation [17]. PLEKHF1, or LAPF,
acts as a pro-apoptotic protein through induction of
the lysosomal-mitochondrial apoptotic pathway [18].
Finally, IL1R2, a non-signalling decoy receptor for
IL-1, attenuates IL-1 based inflammatory processes
[19–21], and has been demonstrated to be over-
expressed in multiple processes including organ
rejection [22], ulcerative colitis [23], inflammatory
arthritis and auto-immune disorders [24,25]. In the
domain of clinical variables, conditioning regimen
intensity has been previously found to be important
in cGVHD diagnostic biomarker discovery [15].
Whilst not a consistent risk factor across multiple
studies, some association has been seen between
recipient CMV serostatus and cGVHD [26]. Further
investigation into early viral reactivation post-HCT
and cGVHD risk is not possible in our study [27,28].
In contrast to these positive findings, our work also
demonstrates lack of verification of many previously
reported cGVHD diagnostic markers. The majority of
the studied RNA and protein markers demonstrated
no significant differences between cGVHD cases and
controls. Major contributors to the limited validation
achieved in this study may include the following:
First, several of the candidates studied here were pre-
viously identified in small discovery studies that
lacked independent cohort verification. As well, other
technical and patient-specific factors may threaten the
ability to replicate prior findings. Poor replication of
biomarkers in verification studies is common given
the heterogeneity of patient demographics, many
unknown or unstudied clinical variables and disease
heterogeneity. In contrast, robust markers suitable for
ultimate clinical application should maintain perform-
ance across independent patient cohorts.
Our study is strengthened by its design, including
the following: verification of previously reported
markers in independent group of chronic GVHD
patients and non-GVHD controls, careful selection of
matched cases/controls, reporting of essential patient,
disease, transplantation, therapy characteristics and
attention to potentially confounding variables.
Amongst limitations, we acknowledge the heteroge-
neity in chronic GVHD characteristics amongst
included subjects in the context of an observational
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Figure 6. Discrimination of GVHD subtypes by combining RNA biomarkers and clinical variables. RNA biomarkers and clinical variables
were used to discriminate GVHD subtypes, prevalent and incident. (A) ROC curve for discriminating prevalent versus incident by RNA
biomarkers selected from differential analysis, insert as biomarkers used to generate the corresponding ROC. (B) Significant test pro-
file of clinical variable response to three top adjusted biomarkers, CD56, IRS2 and CD19. (C) BGA classification of subtypes of preva-
lent and incident by using 3 adjusted RNA biomarkers and one clinical variable, NIH 0-3 GI involvement. Suffix of subtype denotes
the GI score. That is, prevalent.1 and incident.1 represents prevalent and incident with GI score of 1. (D) ROC curve for discriminating
prevalent.1 and incident.1 by combining three adjusted biomarkers (inserted list) and GI score. (E) BGA classification of subtypes of
prevalent and incident with combining 3 adjusted biomarkers and two clinical variables, GI and mouth score. The first suffix of sub-
type labels denotes GI as the same as C, whilst the second suffix represents the score of mouth.
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cohort study (not a controlled trial), and the moderate
sample size. Perhaps most importantly, using several
analytic approaches, diagnostic accuracy for the studied
markers alone was largely poor. Only the combination
of clinical variables and biologic markers achieved suf-
ficient accuracy to be considered useful. Finally, the
studied markers do not perform well overall to segre-
gate cases with higher overall (NIH 0-3 score) cGVHD
severity, and overlap versus classic cGVHD status.
In summary, our study demonstrates that a small
subset of RNA biomarkers, when combined with spe-
cific clinical variables, can improve the accuracy for
cGVHD diagnosis. This combined biomarker/clinical
variable panel needs to be further validated in inde-
pendent studies.
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